Developing a non-invasive, autonomous robotic platform capable of destroying tissue at a sub-cellular level
Sign up today and learn more about HistoSonics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About HistoSonics Stock
HistoSonics, Inc. was created to advance the development of histotripsy, a science discovered and developed by leading scientists at the University of Michigan to provide improved therapies for patients. According to the company, its exclusive license to intellectual property, significant financial support, and strategic partnerships have helped HistoSonics develop Robotically Assisted Sonic Therapy (RAST)™, a novel beam therapy capable of destroying tissue at a sub-cellular level. HistoSonics’ team of specialists and industry leaders is based in Ann Arbor, Michigan.
VP of Regulatory & Clinical Affairs
VP of Research & Development
VP of Operations
President & CEO
VP of Marketing